{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=42&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Orlando",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 6848,
    "total_pages": 685,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=43&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=41&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T04:58:46.903Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00406952",
      "title": "Study for Evaluating Different Methods of Measuring Depression Treatment Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "electronic diary",
          "type": "PROCEDURE"
        },
        {
          "name": "Sertraline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "voice acoustics",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 165,
      "start_date": "2006-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2008-08-21",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 12,
      "location_summary": "Norwich, Connecticut • Aventura, Florida • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00406952"
    },
    {
      "nct_id": "NCT00103649",
      "title": "18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "xaliproden (SR57746A)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1306,
      "start_date": "2003-11",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2008-08-21",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 97,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103649"
    },
    {
      "nct_id": "NCT05776134",
      "title": "Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Mantle Cell Lymphoma",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Brexucabtagene Autoleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05776134"
    },
    {
      "nct_id": "NCT03543852",
      "title": "SurvivorLink: Scalability of an Electronic Personal Health Record",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Childhood Cancer"
      ],
      "interventions": [
        {
          "name": "SurvivorLink",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 542,
      "start_date": "2021-06-14",
      "completion_date": "2024-12-15",
      "has_results": true,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03543852"
    },
    {
      "nct_id": "NCT04539938",
      "title": "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2 Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-12-01",
      "completion_date": "2025-03-07",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 140,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Alhambra, California + 92 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04539938"
    },
    {
      "nct_id": "NCT01965158",
      "title": "Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid-induced Constipation"
      ],
      "interventions": [
        {
          "name": "Naldemedine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 547,
      "start_date": "2013-08-29",
      "completion_date": "2015-01-22",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01965158"
    },
    {
      "nct_id": "NCT02807285",
      "title": "Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-09-07",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 52 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807285"
    },
    {
      "nct_id": "NCT01290887",
      "title": "Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Asthma"
      ],
      "interventions": [
        {
          "name": "Reslizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 1052,
      "start_date": "2011-06",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-06-06",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 48,
      "location_summary": "Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290887"
    },
    {
      "nct_id": "NCT01798004",
      "title": "Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ganglioneuroblastoma",
        "Stage 1 Neuroblastoma",
        "Stage 2 Neuroblastoma",
        "Stage 2A Neuroblastoma",
        "Stage 2B Neuroblastoma",
        "Stage 3 Neuroblastoma",
        "Stage 4 Neuroblastoma",
        "Stage 4S Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 150,
      "start_date": "2013-04-09",
      "completion_date": "2024-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 113,
      "location_summary": "Birmingham, Alabama • Downey, California • Duarte, California + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01798004"
    },
    {
      "nct_id": "NCT00005947",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "sipuleucel-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dendreon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 127,
      "start_date": "1999-11",
      "completion_date": "2004-09",
      "has_results": true,
      "last_update_posted_date": "2010-11-01",
      "last_synced_at": "2026-11-03T04:58:46.903Z",
      "location_count": 34,
      "location_summary": "Duarte, California • Loma Linda, California • Rancho Mirage, California + 26 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005947"
    }
  ]
}